1
|
Nemoto M, Kawanishi N, Kambayashi Y, Bannai H, Yamanaka T, Tsujimura K. Detection of equine influenza virus gene in the air around infected horses. Vet Microbiol 2025; 302:110388. [PMID: 39823717 DOI: 10.1016/j.vetmic.2025.110388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2024] [Revised: 01/07/2025] [Accepted: 01/10/2025] [Indexed: 01/20/2025]
Abstract
Equine influenza virus (EIV) can be transmitted by inhalation of aerosolized droplets, direct contact, and contaminated fomites. However, to our knowledge, there are no reports of the recovery of EIV from the air surrounding infected horses. Here, we evaluated whether EIV can be recovered from the air in the stalls of experimentally infected horses by using an air sampler. Furthermore, we examined whether rapid molecular test kits with reaction times of less than 30 min can detect EIV from air samples for potential field application. Two horses kept in individual stalls were experimentally infected with EIV. Air samples were collected daily by using an air sampler until 13 days post-inoculation (dpi). Viral genes were detected in 26 out of 28 air samples from both horses at 1-13 dpi by real-time RT-PCR. A rapid molecular test kit based on real-time RT-PCR detected viral genes in 23 air samples from one horse at 1-9 and 12 dpi, and from the other at 1-13 dpi. These findings confirm that horses infected with EIV shed the virus into the air. Air sampling is safe for humans and horses and avoids the potential for injury when nasopharyngeal swabs need to be collected from untrained or aggressive horses. EIV RNA was detected in the air samples by using real-time RT-PCR or the rapid molecular test kit before the horses showed clinical signs. Thus, air samplers can detect EIV RNA as early as possible through routine testing in locations such as quarantine facilities.
Collapse
Affiliation(s)
- Manabu Nemoto
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan.
| | - Nanako Kawanishi
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | | | - Hiroshi Bannai
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Takashi Yamanaka
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Koji Tsujimura
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| |
Collapse
|
2
|
Katzmarzyk M, Naughton R, Sitaras I, Jacobsen H, Higdon MM, Deloria Knoll M. Evaluating the Quality of Studies Assessing COVID-19 Vaccine Neutralizing Antibody Immunogenicity. Vaccines (Basel) 2024; 12:1238. [PMID: 39591141 PMCID: PMC11598362 DOI: 10.3390/vaccines12111238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2024] [Revised: 10/22/2024] [Accepted: 10/27/2024] [Indexed: 11/28/2024] Open
Abstract
Objective: COVID-19 vaccine-neutralizing antibodies provide early data on potential vaccine effectiveness, but their usefulness depends on study reliability and reporting quality. Methods: We systematically evaluated 50 published post-vaccination neutralizing antibody studies for key parameters that determine study and data quality regarding sample size, SARS-CoV-2 infection, vaccination regimen, sample collection period, demographic characterization, clinical characterization, experimental protocol, live virus and pseudo-virus details, assay standardization, and data reporting. Each category was scored from very high to low or unclear quality, with the lowest score determining the overall study quality score. Results: None of the studies attained an overall high or very high score, 8% (n = 4) attained moderate, 42% (n = 21) low, and 50% (n = 25) unclear. The categories with the fewest studies assessed as ≥ high quality were SARS-CoV-2 infection (42%), sample size (30%), and assay standardization (14%). Overall quality was similar over time. No association between journal impact factor and quality score was found. Conclusions: We found that reporting in neutralization studies is widely incomplete, limiting their usefulness for downstream analyses.
Collapse
Affiliation(s)
- Maeva Katzmarzyk
- Department of Viral Immunology, Helmholtz Center for Infection Research, 38124 Braunschweig, Germany
| | | | - Ioannis Sitaras
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Henning Jacobsen
- Department of Viral Immunology, Helmholtz Center for Infection Research, 38124 Braunschweig, Germany
| | - Melissa M. Higdon
- International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Maria Deloria Knoll
- International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| |
Collapse
|
3
|
Antigenic comparison of H3N8 equine influenza viruses belonging to Florida sublineage clade 1 between vaccine strains and North American strains isolated in 2021-2022. Arch Virol 2023; 168:94. [PMID: 36806782 DOI: 10.1007/s00705-023-05720-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 01/24/2023] [Indexed: 02/23/2023]
Abstract
Equine influenza virus strains of Florida sublineage clade 1 (Fc1) have been circulating in North America. In this study, virus neutralization assays were performed to evaluate antigenic differences between Fc1 vaccine strains and North American Fc1 strains isolated in 2021-2022, using equine antisera against A/equine/South Africa/4/2003 (a vaccine strain recommended by the World Organisation for Animal Health) and A/equine/Ibaraki/1/2007 (a Japanese vaccine strain). Antibody titers against four North American Fc1 strains isolated in 2021-2022 were comparable to those against the homologous vaccine strains. These results suggest that current Fc1 vaccine strains are effective against North American strains from 2021-2022.
Collapse
|
4
|
Colgate VA, Newton JR. Equine influenza bi-annual boosters: What does the evidence tell us? Equine Vet J 2023; 55:147-152. [PMID: 36382414 DOI: 10.1111/evj.13898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 10/28/2022] [Indexed: 11/18/2022]
Affiliation(s)
- Victoria A Colgate
- Equine Infectious Disease Surveillance, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
| | - J Richard Newton
- Equine Infectious Disease Surveillance, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
| |
Collapse
|
5
|
Ohta M, Kambayashi Y, Mita H, Kuroda T, Bannai H, Tsujimura K, Yamanaka T, Garvey M, Cullinane A, Yamayoshi S, Kawaoka Y, Nemoto M. Protective efficacy of a reverse genetics-derived inactivated vaccine against equine influenza virus in horses. Vaccine 2022; 40:6362-6366. [PMID: 36175213 DOI: 10.1016/j.vaccine.2022.09.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 09/09/2022] [Accepted: 09/15/2022] [Indexed: 01/27/2023]
Abstract
Updating vaccine strains is essential to control equine influenza. We evaluated the protective efficacy of an inactivated equine influenza vaccine derived from viruses generated by reverse genetics (RG) in horses in an experimental viral challenge study. Wild-type (WT) virus (A/equine/Tipperary/1/2019) and virus generated by RG (consisting of hemagglutinin and neuraminidase genes from A/equine/Tipperary/1/2019 and six other genes from high-growth A/Puerto Rico/8/34) were inactivated by formalin for vaccine use. Twelve 1-year-old naïve horses with no antibodies against equine influenza virus were assigned to three groups (each n = 4): control, WT, and RG. They were vaccinated twice, 4 weeks apart, and were challenged with A/equine/Tipperary/1/2019 2 weeks after the second vaccination. All four horses in the control group and one horse in the WT group had pyrexia for multiple days and respiratory illness, and one horse in the RG group had pyrexia for 2 days without respiratory illness. The mean rectal temperatures and the mean concentrations of serum amyloid A in the WT and RG groups were significantly lower than those in the control group, with no significant differences between them. The WT and RG vaccines significantly reduced viral shedding relative to the control. The protective efficacy of the RG-derived inactivated vaccine against equine influenza virus is comparable to that of the vaccine derived from WT viruses in horses. The RG technique can make it easy to update equine influenza vaccine strains.
Collapse
Affiliation(s)
- Minoru Ohta
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | | | - Hiroshi Mita
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | - Taisuke Kuroda
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | - Hiroshi Bannai
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | - Koji Tsujimura
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | - Takashi Yamanaka
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | - Marie Garvey
- Virology Unit, Irish Equine Centre, Kildare, Ireland
| | - Ann Cullinane
- Virology Unit, Irish Equine Centre, Kildare, Ireland
| | - Seiya Yamayoshi
- Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan
| | - Yoshihiro Kawaoka
- Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - Manabu Nemoto
- Equine Research Institute, Japan Racing Association, Tochigi, Japan.
| |
Collapse
|
6
|
Ohta M, Bannai H, Kambayashi Y, Tsujimura K, Tamura N, Iwamoto Y, Wakuno A, Yamayoshi S, Kawaoka Y, Nemoto M. Antibody Responses to a Reverse Genetics-Derived Bivalent Inactivated Equine Influenza Vaccine in Thoroughbred Horses. J Equine Vet Sci 2021; 109:103860. [PMID: 34973368 DOI: 10.1016/j.jevs.2021.103860] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 12/20/2021] [Accepted: 12/24/2021] [Indexed: 11/27/2022]
Abstract
Updating vaccine strains is important to control equine influenza (EI). Previously, we reported that a monovalent inactivated EI vaccine derived from a virus generated by reverse genetics (RG) elicited immunogenicity in horses. In the present study, we compared antibody responses to a bivalent inactivated EI vaccine generated by RG and a commercially available bivalent inactivated EI (CO) vaccine derived from wild-type equine influenza viruses in Thoroughbred horses. The CO vaccine contained A/equine/Ibaraki/1/2007 (Florida sub-lineage clade 1) and A/equine/Yokohama/aq13/2010 (Florida sub-lineage clade 2) as vaccine strains. We generated two RG viruses possessing the hemagglutinin and neuraminidase genes from A/equine/Ibaraki/1/2007 or A/equine/Yokohama/aq13/2010. These viruses were inactivated by formalin, and the hemagglutinin titer of the RG vaccine was adjusted to be the same as that of the CO vaccine. Sixteen unvaccinated yearlings (7 for the RG vaccine group and 9 for the CO vaccine group) received two doses of a primary vaccination course four weeks apart. Thirty-two vaccinated adult horses (18 in the RG-vaccinated group and 14 in the CO vaccine group) received a single dose of a booster vaccination. The patterns of hemagglutination inhibition antibody response to the primary and booster vaccinations were similar for the RG and CO groups in unvaccinated yearlings and vaccinated adult horses. These results suggest that a bivalent vaccine derived from RG viruses elicits equivalent immunogenicity to that elicited by a CO vaccine derived from wild-type viruses. RG viruses can, therefore, be used in multivalent as well as monovalent vaccines for horses.
Collapse
Affiliation(s)
- Minoru Ohta
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | - Hiroshi Bannai
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | | | - Koji Tsujimura
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | - Norihisa Tamura
- Equine Research Institute, Japan Racing Association, Tochigi, Japan
| | - Yohei Iwamoto
- Hidaka Training and Research Center, Japan Racing Association, Hokkaido, Japan
| | - Ai Wakuno
- The Horse Racing School, Japan Racing Association, Chiba, Japan
| | - Seiya Yamayoshi
- Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan
| | - Yoshihiro Kawaoka
- Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Manabu Nemoto
- Equine Research Institute, Japan Racing Association, Tochigi, Japan.
| |
Collapse
|
7
|
Equine Influenza Virus and Vaccines. Viruses 2021; 13:v13081657. [PMID: 34452521 PMCID: PMC8402878 DOI: 10.3390/v13081657] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 07/27/2021] [Accepted: 07/28/2021] [Indexed: 01/01/2023] Open
Abstract
Equine influenza virus (EIV) is a constantly evolving viral pathogen that is responsible for yearly outbreaks of respiratory disease in horses termed equine influenza (EI). There is currently no evidence of circulation of the original H7N7 strain of EIV worldwide; however, the EIV H3N8 strain, which was first isolated in the early 1960s, remains a major threat to most of the world's horse populations. It can also infect dogs. The ability of EIV to constantly accumulate mutations in its antibody-binding sites enables it to evade host protective immunity, making it a successful viral pathogen. Clinical and virological protection against EIV is achieved by stimulation of strong cellular and humoral immunity in vaccinated horses. However, despite EI vaccine updates over the years, EIV remains relevant, because the protective effects of vaccines decay and permit subclinical infections that facilitate transmission into susceptible populations. In this review, we describe how the evolution of EIV drives repeated EI outbreaks even in horse populations with supposedly high vaccination coverage. Next, we discuss the approaches employed to develop efficacious EI vaccines for commercial use and the existing system for recommendations on updating vaccines based on available clinical and virological data to improve protective immunity in vaccinated horse populations. Understanding how EIV biology can be better harnessed to improve EI vaccines is central to controlling EI.
Collapse
|
8
|
Abstract
Influenza is an extremely contagious respiratory disease, which predominantly affects the upper respiratory tract. There are four types of influenza virus, and pigs and chickens are considered two key reservoirs of this virus. Equine influenza (EI) virus was first identified in horses in 1956, in Prague. The influenza A viruses responsible for EI are H7N7 and H3N8. Outbreaks of EI are characterized by their visible and rapid spread, and it has been possible to isolate and characterize H3N8 outbreaks in several countries. The clinical diagnosis of this disease is based on the clinical signs presented by the infected animals, which can be confirmed by performing complementary diagnostic tests. In the diagnosis of EI, in the field, rapid antigen detection tests can be used for a first approach. Treatment is based on the management of the disease and rest for the animal. Regarding the prognosis, it will depend on several factors, such as the animal's vaccination status. One of the important points in this disease is its prevention, which can be done through vaccination. In addition to decreasing the severity of clinical signs and morbidity during outbreaks, vaccination ensures immunity for the animals, reducing the economic impact of this disease.
Collapse
|
9
|
Nemoto M, Ohta M, Yamanaka T, Kambayashi Y, Bannai H, Tsujimura K, Yamayoshi S, Kawaoka Y, Cullinane A. Antigenic differences between equine influenza virus vaccine strains and Florida sublineage clade 1 strains isolated in Europe in 2019. Vet J 2021; 272:105674. [PMID: 33941332 DOI: 10.1016/j.tvjl.2021.105674] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Revised: 04/05/2021] [Accepted: 04/07/2021] [Indexed: 01/10/2023]
Abstract
From late 2018 to 2019, equine influenza virus (EIV) strains of Florida sublineage clade 1 (Fc1), which had until then been circulating mainly in the United States, suddenly spread across Europe causing many outbreaks, and Florida sublineage clade 2 (Fc2) strains, which had been circulating mainly in Europe, have not been detected in Europe since 2018. Since 2010, the World Organisation for Animal Health (OIE) has recommended that EIV vaccines contain an Fc1 strain that is like A/equine/South Africa/4/2003 or A/equine/Ohio/2003. Accordingly, Japanese vaccines contain A/equine/Ibaraki/1/2007 as the Fc1 strain. To evaluate the effectiveness of these vaccines against the Fc1 strains detected in Europe in 2019, we performed virus neutralization tests using horse antisera. Challenge viruses used were Irish strain A/equine/Tipperary/1/2019 and two recombinant viruses generated by reverse genetics. Recombinant viruses possessing hemagglutinin (HA) and neuraminidase (NA) derived from A/equine/Tipperary/1/2019 (rA/equine/Tipperary/1/2019) or British strain A/equine/Essex/1/2019 (rA/equine/Essex/1/2019) were generated. Equine antisera against A/equine/South Africa/2003 and A/equine/Ibaraki/2007 were produced by experimental infection. Antibody titers against A/equine/Tipperary/1/2019, rA/equine/Tipperary/1/2019, and rA/equine/Essex/1/2019 were 2.5- to 6.3-fold lower than those against the homologous vaccine strains A/equine/South Africa/4/2003 or A/equine/Ibaraki/2007. These results suggest that the ongoing evolution of the Fc1 viruses may impact on antigenicity and although antibodies against current vaccine strains neutralize the 2019 strains, ongoing surveillance is essential for optimum choice of candidate vaccine strains.
Collapse
Affiliation(s)
- Manabu Nemoto
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan.
| | - Minoru Ohta
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Takashi Yamanaka
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Yoshinori Kambayashi
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Hiroshi Bannai
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Koji Tsujimura
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Seiya Yamayoshi
- Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
| | - Yoshihiro Kawaoka
- Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
| | - Ann Cullinane
- Virology Unit, Irish Equine Centre, Naas, Co. Kildare, W91 RH93 Johnstown, Ireland
| |
Collapse
|
10
|
An Evaluation of Three Different Primary Equine Influenza Vaccination Intervals in Foals. J Equine Vet Sci 2021; 99:103397. [PMID: 33781435 DOI: 10.1016/j.jevs.2021.103397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2020] [Revised: 01/25/2021] [Accepted: 01/25/2021] [Indexed: 11/20/2022]
Abstract
In order to evaluate the effect of three different primary vaccination intervals on EI vaccine response, 21 unvaccinated thoroughbred foals were randomly divided into three groups of 7 and vaccinated with three different intervals of primary immunization (i.e., with 1, 2 or 3 months intervals between V1 and V2, respectively). The antibody response was measured for up to 1 year after the third immunization V3 (administered 6 months after V2) by single radial hemolysis (SRH) assay. All weanlings had seroconverted and exceeded the clinical protection threshold 2 weeks after V2 and 1 month after V3 until the end of the study. Significant differences were measured at the peak of immunity after V2 and for the duration of the immunity gap between V2 and V3. The group with one month primary vaccination interval had a lower immunity peak after V2 (158.05 ± 6.63 mm2) and a wider immunity gap between V2 and V3 (18 weeks) when compared with other groups (i.e., 174.72 ± 6.86 mm2 and 16 weeks for a two months interval, 221.45 ± 14.48 mm2 and 12 weeks for a 3-month interval). The advantage observed in the group with 1 month primary vaccination interval, which induces an earlier protective immunity, is counterbalance with a lower peak of immunity and a wider immunity gap after V2, when compared with foals vaccinated with 2- and 3-month intervals.
Collapse
|
11
|
Nemoto M, Tamura N, Bannai H, Tsujimura K, Kokado H, Ohta M, Yamanaka T. Mutated influenza A virus exhibiting reduced susceptibility to baloxavir marboxil from an experimentally infected horse. J Gen Virol 2020; 100:1471-1477. [PMID: 31526451 DOI: 10.1099/jgv.0.001325] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Baloxavir marboxil (BXM), an inhibitor of the cap-dependent endonuclease of the influenza virus polymerase acidic protein (PA), exerts an antiviral effect against influenza A virus. It has been available in Japan since March 2018. This study evaluated the antiviral efficacy of BXM against equine influenza A virus (EIV) by an experimental challenge study using horses. Six horses were experimentally inoculated with EIV, and BXM was administered to the three horses at 2 days post inoculation. Horses treated with BXM showed milder clinical signs than horses without treatment and shed less virus. These results suggest that BXM is effective against EIV. The PA gene of viruses present in the nasopharyngeal swabs collected from horses treated with BXM was sequenced. Two mutations have been detected in viruses recovered from horses treated with BXM. These mutations were the substitution of isoleucine with threonine at position 38 (PA-I38T) and that of asparagine with aspartic acid at position 675 in PA (PA-N675D). A mutated virus with PA-I38T was less susceptible to BXM than viruses with PA-N675D or without mutation. A PA-I38T mutation has also been detected in viruses recovered from humans treated with BXM and is responsible for the reduction in susceptibility to BXM. This suggests that we should not unthinkingly use BXM for the treatment of EI. BXM is likely to easily induce resistance in influenza A viruses, not only in humans but also in horses.
Collapse
Affiliation(s)
- Manabu Nemoto
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Norihisa Tamura
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Hiroshi Bannai
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Koji Tsujimura
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Hiroshi Kokado
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Minoru Ohta
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Takashi Yamanaka
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| |
Collapse
|
12
|
Abstract
Serologic tests for equine influenza virus (EIV) antibodies are used for many purposes, including retrospective diagnosis, subtyping of virus isolates, antigenic comparison of different virus strains, and measurement of immune responses to EIV vaccines. The hemagglutination inhibition (HI) assay, single radial hemolysis (SRH), and serum micro-neutralization tests are the most widely used for these purposes and are described here. The presence of inhibitors of hemagglutination in equine serum complicates interpretation of HI assay results, and there are alternative protocols (receptor-destroying enzyme, periodate, trypsin-periodate) for their removal. With the EIV H3N8 strains in particular, equine antibody titers may be magnified by pre-treating the HI test antigen with Tween-80 and ether. The SRH assay offers stronger correlations between serum antibody titers and protection from disease. Other tests are sometimes used for specialized purposes such as the neuraminidase-inhibition assay for subtyping, or ELISA for measuring different specific antibody isotypes, and are not described here.
Collapse
Affiliation(s)
- Thomas M Chambers
- Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, USA.
| | - Stephanie E Reedy
- Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, USA
| |
Collapse
|
13
|
Nemoto M, Yamayoshi S, Bannai H, Tsujimura K, Kokado H, Kawaoka Y, Yamanaka T. A single amino acid change in hemagglutinin reduces the cross-reactivity of antiserum against an equine influenza vaccine strain. Arch Virol 2019; 164:2355-2358. [PMID: 31227892 DOI: 10.1007/s00705-019-04328-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2019] [Accepted: 05/27/2019] [Indexed: 12/22/2022]
Abstract
Equine influenza virus is an important pathogen for the horse industry because of its economic impact, and vaccination is a key control measure. Our previous work suggested that a mutation at position 144 in the hemagglutinin of Florida sublineage clade 2 viruses reduces the cross-neutralizing activity of antiserum against a former vaccine strain. To confirm this suggestion, here, we generated viruses by reverse genetics. Antibody titers against the mutated viruses were one-tenth to one-sixteenth of those against the former vaccine strain. Our findings confirm that this single amino acid substitution reduces the cross-reactivity of antiserum against this former Japanese vaccine.
Collapse
Affiliation(s)
- Manabu Nemoto
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan.
| | - Seiya Yamayoshi
- Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - Hiroshi Bannai
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Koji Tsujimura
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Hiroshi Kokado
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Yoshihiro Kawaoka
- Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.,Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, WI, USA
| | - Takashi Yamanaka
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| |
Collapse
|
14
|
Equine Influenza Virus in Asia: Phylogeographic Pattern and Molecular Features Reveal Circulation of an Autochthonous Lineage. J Virol 2019; 93:JVI.00116-19. [PMID: 31019053 DOI: 10.1128/jvi.00116-19] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 04/09/2019] [Indexed: 12/12/2022] Open
Abstract
Equine influenza virus (EIV) causes severe acute respiratory disease in horses. Currently, the strains belonging to the H3N8 subtype are divided into two clades, Florida clade 1 (FC1) and Florida clade 2 (FC2), which emerged in 2002. Both FC1 and FC2 clades were reported in Asian and Middle East countries in the last decade. In this study, we described the evolution, epidemiology, and molecular characteristic of the EIV lineages, with focus on those detected in Asia from 2007 to 2017. The full genome phylogeny showed that FC1 and FC2 constituted separate and divergent lineages, without evidence of reassortment between the clades. While FC1 evolved as a single lineage, FC2 showed a divergent event around 2004 giving rise to two well-supported and coexisting sublineages, European and Asian. Furthermore, two different spread patterns of EIV in Asian countries were identified. The FC1 outbreaks were caused by independent introductions of EIV from the Americas, with the Asian isolates genetically similar to the contemporary American lineages. On the other hand, the FC2 strains detected in Asian mainland countries conformed to an autochthonous monophyletic group with a common ancestor dated in 2006 and showed evidence of an endemic circulation in a local host. Characteristic aminoacidic signature patterns were detected in all viral proteins in both Asian-FC1 and FC2 populations. Several changes were located at the top of the HA1 protein, inside or near antigenic sites. Further studies are needed to assess the potential impact of these antigenic changes in vaccination programs.IMPORTANCE The complex and continuous antigenic evolution of equine influenza viruses (EIVs) remains a major hurdle for vaccine development and the design of effective immunization programs. The present study provides a comprehensive analysis showing the EIV evolutionary dynamics, including the spread and circulation within the Asian continent and its relationship to global EIV populations over a 10-year period. Moreover, we provide a better understanding of EIV molecular evolution in Asian countries and its consequences on the antigenicity. The study underscores the association between the global horse movement and the circulation of EIV in this region. Understanding EIV evolution is imperative in order to mitigate the risk of outbreaks affecting the horse industry and to help with the selection of the viral strains to be included in the formulation of future vaccines.
Collapse
|
15
|
Daly JM, Murcia PR. Strategic implementation of vaccines for control of equine influenza. Equine Vet J 2018; 50:153-154. [PMID: 29392805 DOI: 10.1111/evj.12794] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- J M Daly
- School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington, Leicestershire, UK
| | - P R Murcia
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary Life Science, University of Glasgow, Centre for Virus Research, Glasgow, UK
| |
Collapse
|
16
|
Singh RK, Dhama K, Karthik K, Khandia R, Munjal A, Khurana SK, Chakraborty S, Malik YS, Virmani N, Singh R, Tripathi BN, Munir M, van der Kolk JH. A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies. Front Microbiol 2018; 9:1941. [PMID: 30237788 PMCID: PMC6135912 DOI: 10.3389/fmicb.2018.01941] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Accepted: 07/31/2018] [Indexed: 01/23/2023] Open
Abstract
Among all the emerging and re-emerging animal diseases, influenza group is the prototype member associated with severe respiratory infections in wide host species. Wherein, Equine influenza (EI) is the main cause of respiratory illness in equines across globe and is caused by equine influenza A virus (EIV-A) which has impacted the equine industry internationally due to high morbidity and marginal morality. The virus transmits easily by direct contact and inhalation making its spread global and leaving only limited areas untouched. Hitherto reports confirm that this virus crosses the species barriers and found to affect canines and few other animal species (cat and camel). EIV is continuously evolving with changes at the amino acid level wreaking the control program a tedious task. Until now, no natural EI origin infections have been reported explicitly in humans. Recent advances in the diagnostics have led to efficient surveillance and rapid detection of EIV infections at the onset of outbreaks. Incessant surveillance programs will aid in opting a better control strategy for this virus by updating the circulating vaccine strains. Recurrent vaccination failures against this virus due to antigenic drift and shift have been disappointing, however better understanding of the virus pathogenesis would make it easier to design effective vaccines predominantly targeting the conserved epitopes (HA glycoprotein). Additionally, the cold adapted and canarypox vectored vaccines are proving effective in ceasing the severity of disease. Furthermore, better understanding of its genetics and molecular biology will help in estimating the rate of evolution and occurrence of pandemics in future. Here, we highlight the advances occurred in understanding the etiology, epidemiology and pathobiology of EIV and a special focus is on designing and developing effective diagnostics, vaccines and control strategies for mitigating the emerging menace by EIV.
Collapse
Affiliation(s)
- Raj K. Singh
- ICAR-Indian Veterinary Research Institute, Bareilly, India
| | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India
| | - Kumaragurubaran Karthik
- Central University Laboratory, Tamil Nadu Veterinary and Animal Sciences University, Chennai, India
| | - Rekha Khandia
- Department of Biochemistry and Genetics, Barkatullah University, Bhopal, India
| | - Ashok Munjal
- Department of Biochemistry and Genetics, Barkatullah University, Bhopal, India
| | | | - Sandip Chakraborty
- Department of Veterinary Microbiology, College of Veterinary Sciences and Animal Husbandry, West Tripura, India
| | - Yashpal S. Malik
- Division of Biological Standardization, ICAR-Indian Veterinary Research Institute, Bareilly, India
| | | | - Rajendra Singh
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India
| | | | - Muhammad Munir
- Division of Biomedical and Life Sciences, Lancaster University, Lancaster, United Kingdom
| | - Johannes H. van der Kolk
- Division of Clinical Veterinary Medicine, Swiss Institute for Equine Medicine (ISME), Vetsuisse Faculty, University of Bern and Agroscope, Bern, Switzerland
| |
Collapse
|
17
|
Gildea S, Garvey M, Lyons P, Lyons R, Gahan J, Walsh C, Cullinane A. Multifocal Equine Influenza Outbreak with Vaccination Breakdown in Thoroughbred Racehorses. Pathogens 2018; 7:pathogens7020043. [PMID: 29673169 PMCID: PMC6027538 DOI: 10.3390/pathogens7020043] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 04/10/2018] [Accepted: 04/13/2018] [Indexed: 01/24/2023] Open
Abstract
Equine influenza (EI) outbreaks occurred on 19 premises in Ireland during 2014. Disease affected thoroughbred (TB) and non-TB horses/ponies on a variety of premises including four racing yards. Initial clinical signs presented on 16 premises within a two-month period. Extensive field investigations were undertaken, and the diagnostic effectiveness of a TaqMan RT-PCR assay was demonstrated in regularly-vaccinated and sub-clinically-affected horses. Epidemiological data and repeat clinical samples were collected from 305 horses, of which 40% were reported as clinically affected, 39% were identified as confirmed cases and 11% were sub-clinically affected. Multivariable analysis demonstrated a significant association between clinical signs and age, vaccination status and number of vaccine doses received. Vaccine breakdown was identified in 31% of horses with up to date vaccination records. This included 27 horses in four different racing yards. Genetic and antigenic analysis identified causal viruses as belonging to Clade 2 of the Florida sublineage (FCL2). At the time of this study, no commercially available EI vaccine in Ireland had been updated in line with World Organisation for Animal Health (OIE) recommendations to include a FCL2 virus. The findings of this study highlight the potential ease with which EI can spread among partially immune equine populations.
Collapse
Affiliation(s)
- Sarah Gildea
- Virology Unit, The Irish Equine Centre, Johnstown, Naas, Co. Kildare W91 RH93, Ireland.
| | - Marie Garvey
- Virology Unit, The Irish Equine Centre, Johnstown, Naas, Co. Kildare W91 RH93, Ireland.
| | - Pamela Lyons
- Virology Unit, The Irish Equine Centre, Johnstown, Naas, Co. Kildare W91 RH93, Ireland.
| | - Rachel Lyons
- Virology Unit, The Irish Equine Centre, Johnstown, Naas, Co. Kildare W91 RH93, Ireland.
| | - Jacinta Gahan
- Virology Unit, The Irish Equine Centre, Johnstown, Naas, Co. Kildare W91 RH93, Ireland.
| | - Cathal Walsh
- Department of Mathematics and Statistics, University of Limerick, Castletroy, Limerick V94 T9PX, Ireland.
| | - Ann Cullinane
- Virology Unit, The Irish Equine Centre, Johnstown, Naas, Co. Kildare W91 RH93, Ireland.
| |
Collapse
|
18
|
Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Matsumura T, Kokado H, Gildea S, Cullinane A. Neutralization antibody response to booster/priming immunization with new equine influenza vaccine in Japan. J Vet Med Sci 2017; 80:382-386. [PMID: 29237998 PMCID: PMC5836781 DOI: 10.1292/jvms.17-0538] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Equine influenza (EI) vaccine has been widely used. However, the causative EI virus
(H3N8) undergoes continuous antigenic drift, and the vaccine strains must be periodically
reviewed and if necessary, updated to maintain vaccine efficacy against circulating
viruses. In 2016, the Japanese vaccine was updated by replacing the old viruses with the
Florida sub-lineage Clade (Fc) 2 virus, A/equine/Yokohama/aq13/2010 (Y10). We investigated
the virus neutralization (VN) antibody response to Fc2 viruses currently circulating in
Europe, after booster or primary immunization with the new vaccine. These European viruses
have the amino acid substitution A144V or I179V of the hemagglutinin. In horses that had
previously received a primary course and bi-annual boosters with the old vaccine booster,
immunization with the updated vaccine increased the VN antibody levels against the
European Fc2 viruses as well as Y10. There were no significant differences in the VN
titers against Y10 and the Fc2 viruses with A144V or I179V substitution in horses that had
received a primary course of the updated vaccine. However, a mixed primary course where
the first dose was the old vaccine and the second dose was the updated vaccine, reduced VN
titers against the European viruses compared to that against Y10. In summary, the new
vaccine affords horses protective level of VN titers against the Fc2 viruses carrying
A144V or I179V substitution, but our results suggest that the combination of the old and
new vaccines for primary immunization would not be optimum.
Collapse
Affiliation(s)
- Takashi Yamanaka
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Manabu Nemoto
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Hiroshi Bannai
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Koji Tsujimura
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Tomio Matsumura
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Hiroshi Kokado
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Sarah Gildea
- Irish Equine Centre, Johnstown, Naas, Co., Kildare, W91 RH93, Ireland
| | - Ann Cullinane
- Irish Equine Centre, Johnstown, Naas, Co., Kildare, W91 RH93, Ireland
| |
Collapse
|
19
|
Yang H, Xiao Y, Meng F, Sun F, Chen M, Cheng Z, Chen Y, Liu S, Chen H. Emergence of H3N8 equine influenza virus in donkeys in China in 2017. Vet Microbiol 2017; 214:1-6. [PMID: 29408020 DOI: 10.1016/j.vetmic.2017.11.033] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 11/26/2017] [Accepted: 11/26/2017] [Indexed: 11/26/2022]
Abstract
Equine influenza virus is a major respiratory pathogen in horses. Although both horses and donkeys belong to the genus Equus, donkey infection with influenza viruses is rare. In March 2017, an influenza outbreak occurred in donkeys in Shandong province, China. The causative virus, A/donkey/Shandong/1/2017(H3N8), was isolated from a dead donkey. Genetic analysis indicated that the virus originated from influenza A (H3N8) clade 2 of the Florida sub-lineage that has been circulating in Asian equine populations. Comparison of the deduced amino acid sequence of the HA gene of this causative virus with that of the A/equine/Richmond/1/2007 vaccine strain showed that substitutions had occurred in the antigenic regions A, B, and C. This study provides insight into the currently circulating and newly emerging H3N8 strains in donkeys in China.
Collapse
Affiliation(s)
- Huanliang Yang
- State Key Laboratory of Veterinary Biotechnology-Harbin Veterinary Research Institute, CAAS, Harbin, China
| | - Yihong Xiao
- Department of Fundamental Veterinary Medicine, College of Animal Science and Veterinary Medicine-Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, Shandong, China
| | - Fei Meng
- State Key Laboratory of Veterinary Biotechnology-Harbin Veterinary Research Institute, CAAS, Harbin, China
| | - Fachao Sun
- Department of Fundamental Veterinary Medicine, College of Animal Science and Veterinary Medicine-Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, Shandong, China
| | - Meng Chen
- Department of Fundamental Veterinary Medicine, College of Animal Science and Veterinary Medicine-Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, Shandong, China
| | - Zilong Cheng
- Department of Fundamental Veterinary Medicine, College of Animal Science and Veterinary Medicine-Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, Shandong, China
| | - Yan Chen
- State Key Laboratory of Veterinary Biotechnology-Harbin Veterinary Research Institute, CAAS, Harbin, China
| | - Sidang Liu
- Department of Fundamental Veterinary Medicine, College of Animal Science and Veterinary Medicine-Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, Shandong, China
| | - Hualan Chen
- State Key Laboratory of Veterinary Biotechnology-Harbin Veterinary Research Institute, CAAS, Harbin, China.
| |
Collapse
|
20
|
Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Kondo T, Matsumura T, Fu TQH, Fernandez CJ, Gildea S, Cullinane A. Rapid diagnosis of equine influenza by highly sensitive silver amplification immunochromatography system. J Vet Med Sci 2017; 79:1061-1063. [PMID: 28458275 PMCID: PMC5487783 DOI: 10.1292/jvms.17-0105] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Equine influenza (EI) is a respiratory disease caused by equine influenza A virus (EIV,
H3N8) infection. Rapid diagnosis is essential to limit the disease spread. We previously
reported that some rapid antigen detection (RAD) tests are fit for diagnosing EI although
their sensitivity is not optimal. Here, we evaluated the performance of the newly
developed RAD test using silver amplification immunochromatography (Quick Chaser Auto Flu
A, B: QCA) to diagnose EI. The detection limits of QCA for EIVs were five-fold lower than
the conventional RAD tests. The duration of virus antigen detection in the infected horses
was longer than the conventional RAD tests. We conclude that QCA could be a valuable
diagnostic method for EI.
Collapse
Affiliation(s)
- Takashi Yamanaka
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Manabu Nemoto
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Hiroshi Bannai
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Koji Tsujimura
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Takashi Kondo
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Tomio Matsumura
- Equine Research Institute, the Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi 329-0412, Japan
| | - Tao Qi Huang Fu
- Agri-Food & Veterinary Authority of Singapore, Animal and Plant Health Centre, 6 Perahu Road, 718827 Singapore
| | - Charlene Judith Fernandez
- Agri-Food & Veterinary Authority of Singapore, Animal and Plant Health Centre, 6 Perahu Road, 718827 Singapore
| | - Sarah Gildea
- Irish Equine Centre, Johnstown, Naas, Co. Kildare, W91 RH93 Ireland
| | - Ann Cullinane
- Irish Equine Centre, Johnstown, Naas, Co. Kildare, W91 RH93 Ireland
| |
Collapse
|
21
|
Evolution and Divergence of H3N8 Equine Influenza Viruses Circulating in the United Kingdom from 2013 to 2015. Pathogens 2017; 6:pathogens6010006. [PMID: 28208721 PMCID: PMC5371894 DOI: 10.3390/pathogens6010006] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Revised: 01/20/2017] [Accepted: 01/22/2017] [Indexed: 12/18/2022] Open
Abstract
Equine influenza viruses (EIV) are a major cause of acute respiratory disease in horses worldwide and occasionally also affect vaccinated animals. Like other influenza A viruses, they undergo antigenic drift, highlighting the importance of both surveillance and virus characterisation in order for vaccine strains to be kept up to date. The aim of the work reported here was to monitor the genetic and antigenic changes occurring in EIV circulating in the UK from 2013 to 2015 and to identify any evidence of vaccine breakdown in the field. Virus isolation, reverse transcription polymerase chain reaction (RT-PCR) and sequencing were performed on EIV-positive nasopharyngeal swab samples submitted to the Diagnostic Laboratory Services at the Animal Health Trust (AHT). Phylogenetic analyses were completed for the haemagglutinin-1 (HA1) and neuraminidase (NA) genes using PhyML and amino acid sequences compared against the current World Organisation for Animal Health (OIE)-recommended Florida clade 2 vaccine strain. Substitutions between the new isolates and the vaccine strain were mapped onto the three-dimensional structure protein structures using PyMol. Antigenic analyses were carried out by haemagglutination inhibition assay using a panel of post-infection ferret antisera. Sixty-nine outbreaks of equine influenza in the UK were reported by the AHT between January 2013 and December 2015. Forty-seven viruses were successfully isolated in eggs from 41 of the outbreaks. Only three cases of vaccine breakdown were identified and in each case the vaccine used contained a virus antigen not currently recommended for equine influenza vaccines. Nucleotide sequencing of the HA and NA genes revealed that all of the viruses belonged to the Florida clade 2 sub-lineage of H3N8 EIV. Phylogenetic and sequence analyses showed that the two sub-populations, previously identified within clade 2, continued to circulate and had accrued further amino acid substitutions. Antigenic characterisation using post-infection ferret antisera in haemagglutination inhibition assays however, failed to detect any marked antigenic differences between the isolates. These findings show that Florida clade 2 EIV continue to circulate in the UK and support the current OIE recommendation to include an example of Florida clade 2 in vaccines.
Collapse
|
22
|
Abstract
Japan established a vaccine selection system, in which a committee evaluates veterinary influenza vaccines to determine if the vaccine should be updated. In
2013, it was concluded that the present equine influenza vaccine strains did not have to be updated, but clade 2 (Fc2) viruses of the Florida sublineage should
be included. We collected three Fc2 viruses as candidates and conducted comparative tests. Results indicated that A/equine/Carlow/2011 (H3N8) is not suitable,
because of its unstable antigenic characteristics. A comparison between A/equine/Richmond/1/2007 (H3N8) (Richmond/07) and A/equine/Yokohama/aq13/2010 (H3N8)
(Yokohama/10) in eggs showed that they shared equal growth properties. Immunogenicity test in mice showed that Yokohama/10 induced higher HI antibody titers
than Richmond/07. Therefore, we concluded that Yokohama/10 was the most suitable strain.
Collapse
Affiliation(s)
- Koichiro Gamoh
- National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries, 1-15-1 Tokura, Kokubunji, Tokyo 185-8511, Japan
| | | |
Collapse
|
23
|
Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Kondo T, Matsumura T, Gildea S, Cullinane A. Assessment of antigenic difference of equine influenza virus strains by challenge study in horses. Influenza Other Respir Viruses 2016; 10:536-539. [PMID: 27465864 PMCID: PMC5059955 DOI: 10.1111/irv.12418] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/18/2016] [Indexed: 12/02/2022] Open
Abstract
We previously reported that horse antiserum against the Japanese equine influenza vaccine virus, A/equine/La Plata/1993 (LP93) exhibited reduced cross-neutralization against some Florida sublineage Clade (Fc) 2 viruses, for example, A/equine/Carlow/2011 (CL11). As a result, Japanese vaccine manufacturers will replace LP93 with A/equine/Yokohama/aq13/2010 (Y10, Fc2). To assess the benefit of updating the vaccine, five horses vaccinated with inactivated Y10 vaccine and five vaccinated with inactivated LP93 were challenged by exposure to a nebulized aerosol of CL11. The durations of pyrexia (≥38.5°C) and other adverse clinical symptoms experienced by the Y10 group were significantly shorter than those of the LP93 group.
Collapse
Affiliation(s)
- Takashi Yamanaka
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan.
| | - Manabu Nemoto
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
- Virology Unit, Irish Equine Centre, Johnstown, Naas, Co. Kildare, Ireland
| | - Hiroshi Bannai
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Koji Tsujimura
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Takashi Kondo
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Tomio Matsumura
- Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan
| | - Sarah Gildea
- Virology Unit, Irish Equine Centre, Johnstown, Naas, Co. Kildare, Ireland
| | - Ann Cullinane
- Virology Unit, Irish Equine Centre, Johnstown, Naas, Co. Kildare, Ireland
| |
Collapse
|
24
|
Kinsley R, Scott SD, Daly JM. Controlling equine influenza: Traditional to next generation serological assays. Vet Microbiol 2016; 187:15-20. [PMID: 27066704 DOI: 10.1016/j.vetmic.2016.03.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Revised: 02/29/2016] [Accepted: 03/08/2016] [Indexed: 01/20/2023]
Abstract
Serological assays provide an indirect route for the recognition of infectious agents via the detection of antibodies against the infectious agent of interest within serum. Serological assays for equine influenza A virus can be applied for different purposes: diagnosing infections; subtyping isolates; surveillance of circulating strains; and to evaluate the efficacy of vaccines before they reach the market. Haemagglutination inhibition (HI) and single radial haemolysis (SRH) assays are most commonly used in the equine field. This review outlines how both these assays together with virus neutralization (VN) and ELISA are performed, interpreted and applied for the control of equine influenza, giving the limitations and advantages of each. The pseudotyped virus neutralization assay (PVNA) is also discussed as a promising prospect for the future of equine influenza virus serology.
Collapse
Affiliation(s)
- Rebecca Kinsley
- Viral Pseudotype Unit, School of Pharmacy, University of Kent, Central Avenue, Chatham Maritime ME4 4TB, UK.
| | - Simon D Scott
- Viral Pseudotype Unit, School of Pharmacy, University of Kent, Central Avenue, Chatham Maritime ME4 4TB, UK.
| | - Janet M Daly
- School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Leicestershire LE12 5RD, UK.
| |
Collapse
|